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A B S T R A C T
The increasing incidence of aciclovir- (ACV) resistant strains in patients with ocular herpes simplex virus (HSV)
infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal
antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its eﬃcacy towards ACV-resistant
infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by mi-
croinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically
treated with mAb hu2c at 24 h prior (pre-exposure prophylaxis) or at 24, 40, and 56 h after infection (post-
exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage.
Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c
may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to
prevent blindness.
1. Introduction
Herpes simplex viruses (HSV) are the leading infectious cause of
blindness in industrialized countries (Farooq and Shukla, 2012) and a
serious health problem in developing countries (Pramod et al., 2000).
After acquisition of HSV via the orofacial route, the virus persists life-
long in the trigeminal ganglia (TGs) (Roizman and Whitley, 2013).
Frequent reactivations of latent HSV are common and may be asso-
ciated with ocular manifestations in the cornea or retina, leading to
visual impairment and blindness. Infections of the cornea lead to the
development of the herpetic stromal keratitis (HSK) (Burrel et al.,
2013), while manifestations in the retina may result in acute retinal
necrosis (ARN) (Lau et al., 2007). HSK is associated with severe im-
mune-mediated inﬂammation of the cornea that may ﬁnally lead to
opacity of the cornea and blindness. Worldwide, roughly 1.5 million
HSK cases are reported (Farooq and Shukla, 2012). ARN is character-
ized by occlusive retinal vasculitis, prominent inﬂammation of the
anterior segment and localized retinal necrosis that is often followed by
optic neuritis and irreversible retinal detachment (Duker and
Blumenkranz, 1991). Moreover, bilateral involvement of ARN (BARN)
may occur within the ﬁrst weeks of disease (Jeon et al.,; Palay et al.,
1991). Further complications may be optic nerve head atrophy, ma-
cular edema, vessel occlusion, ocular hypotony, blindness in the dis-
eased eye(s), glaucoma and encephalitis (Muthiah et al., 2007;
Winterhalter et al.,). HSK and ARN can be caused by both HSV subtypes
HSV-1 and HSV-2 (Grose, 2012; Lau et al., 2007).
Aciclovir has been used to treat ocular HSV manifestations for more
than two decades (Blumenkranz et al., 1986). The current antiviral
treatment for HSK and ARN consists of intravenous or oral therapy with
aciclovir or newer antivirals including famciclovir (prodrug for
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penciclovir) or valaciclovir (prodrug for aciclovir) that have a better
bioavailability in the central nervous system than aciclovir (Tibbetts
et al., 2010). Furthermore, the current therapy for ARN often includes
intraocular injection of antivirals. The antiviral treatment of HSK is
supported by corticosteroids to suppress ocular inﬂammation
(Knickelbein et al., 2009). Beside, prophylactic panretinal argon laser
photocoagulations are performed in many cases of ARN to prevent
retinal detachment (Park and Pavesio, 2008). However, the use of
corticosteroids may cause unwanted side eﬀects such as the develop-
ment of glaucoma and cataract (Carnahan and Goldstein, 2000; Gaudio,
2004). Moreover, long-term antiviral treatment may lead to the de-
velopment of resistance towards aciclovir (Duan et al., 2008; Toriyama
et al., 2014; van Velzen et al., 2013a). The frequency of ACV-resistant
strains among patients with ocular HSV manifestations was described
by van Velzen et al. to be 26% (van Velzen et al., 2013b). ACV or
multidrug-resistant strains could be isolated from patients suﬀering
from HSK (Toriyama et al., 2014; van Velzen et al., 2013b) or ARN
(Dokey et al., 2014; Patel et al., 2010; Tran et al., 2005). Strains re-
sistant to aciclovir were described to be cross-resistant to penciclovir
(Bacon et al., 2003). Alternative antivirals such as cidofovir or foscarnet
are available but may be associated with severe side eﬀects (Broekema
and Dikkers, 2008; Jacobson, 1992). Clearly, a novel eﬀective and well
tolerable antiviral therapy is needed for the treatment and prevention
of ACV-resistant ocular HSV infections. We have recently reported the
development of a humanized, highly neutralizing monoclonal antibody
(mAb hu2c) for the treatment of drug-resistant HSV infections
(Krawczyk et al., 2013, 2011). Systemic mAb hu2c immunotherapy was
capable of protecting highly immunodeﬁcient NOD/SCID mice from
lethal HSV infection. Furthermore, mAb hu2c potently protected mice
from the development of HSK after corneal infection with HSV-1 KOS
(Krawczyk et al., 2015). Based on these prior data, we hypothesized
that mAb hu2c should be particularly suitable for the otherwise hard to
treat ACV-resistant infections of the eye. The aim of the present study
was to clarify whether mAb hu2c is actually capable of preventing the
development of ARN induced by the infection with an ACV-resistant
strain. We used three clinical HSV-1 isolates resistant to ACV that were
isolated from patients with severe HSK. We characterized these isolates
by detailed pheno- and genotypic resistance analysis and identiﬁed
deletions and mutations associated with reduced susceptibility towards
aciclovir. Subsequently, we identiﬁed one isolate that was reliable to
induce the ARN in BALB/c mice according to the previously described
ARN mouse model (Whittum et al., 1984). Similar to the emergence of
ocular infection upon HSV reactivation in humans, the establishment of
disease in this model requires eﬀective viral spread from sensory neu-
rons to the periphery (Whittum et al., 1984). After microinjection of
HSV-1 strain KOS into the anterior chamber of the left eye, the virus
replicates in the anterior segment of this eye. The virus then spreads
from the initially infected eye via parasympathetic neurons to the ip-
silateral ciliary ganglion and reaches the contralateral optic nerve and
retina at days 6–7 post infection resulting in the development of ARN
(Atherton, 2001; Bosem et al., 1990; Cathcart et al., 2009; Vann and
Atherton, 1991; Whittum et al., 1984). Finally, we examined the eﬃ-
cacy of an antibody-based immunotherapy with mAb hu2c towards
ACV-resistant ocular HSV infections in the mouse model of ARN.
2. Material and methods
2.1. Viruses and cells
Three ACV-resistant HSV-1 isolates (HSV-1 ACVr 1, HSV-1 ACVr 2
and HSV-1 ACVr 3) from patients with severe ocular infections were
propagated on Vero cells (American Type Culture Collection, ATCC,
CCL81, Rockville, MD) and stored at −80 °C. HSV-1 ACVr 1 was de-
scribed in van Velzen et al. (2013b) JID; PMID: 23901090 among a
number of isolates derived from patients unsuccessfully treated with
ACV. HSV-1 ACVr 2 was described as isolate R6 in Duan et al. (2008)
JID; PMID: 18627246 and HSV-1 ACVr 3 as isolate R9 A in Duan et al.
(2009) JID; PMID: 19795980. Vero cells were cultured in Dulbecco's
Modiﬁed Eagle Medium (DMEM, Life Technologies Gibco, Darmstadt,
Germany) containing 10% (v/v) FCS.
2.2. Phenotypic and genotypic drug-resistance testing
The susceptibility of HSV-1 strains to the antiviral drugs aciclovir
(ACV), foscarnet (FOS) and cidofovir (CDV) has been analyzed by a
standard plaque reduction assay on Vero cells as previously described
(Kruppenbacher et al., 1994; Pavic et al., 1997). The median inhibitory
concentration (IC50) was deﬁned as the drug concentration that reduced
viral loads by 50% when compared to untreated control infected cells.
Genotypic resistance testing was performed by sequence analysis of the
thymidine kinase (TK) gene UL23 and the polymerase gene UL30. The
identiﬁcation of mutations associated with drug resistance was done
using the online-tool “Mutation Analyzer” at the University of Ulm,
Germany (Analyzer; Chevillotte et al., 2010). All sequences were de-
posited in NCBI GenBank under the accession numbers MF093721 to
MF093726.
2.3. Antibodies
Monoclonal antibodies mAb 2c and mAb hu2c were produced and
puriﬁed as described before (Krawczyk et al., 2013, 2011). Purity was
conﬁrmed by FPLC ≥ 95%. Concentration was measured with a Na-
noDrop 2000 spectrometer (Thermo Scientiﬁc, Wilmington, DE, USA).
2.4. Animal experiments
Female BALB/c mice, 7–8 weeks of age, were purchased from
Charles River Laboratories (Charles River Laboratories, Sulzfeld,
Germany) and maintained under pathogen free conditions according to
the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research. The in vivo experiments were conducted according to the
German legal requirements with the approval of the University Hospital
Essen's animal facility.
2.5. Murine model of HSV retinitis
Female BALB/c mice (Charles River Laboratories, Sulzfeld,
Germany) were infected with ACV-resistant HSV-1 isolates (HSV-1
ACVr 1, HSV-1 ACVr 2 and HSV-1 ACVr 3) to induce HSV retinitis as
previously described (Pepose and Whittum-Hudson, 1987). Brieﬂy,
mice were anesthetized by intraperitoneal injection of ketamine hy-
drochloride (2 mg) and mepivacaine hydrochloride (400 ng). Subse-
quently, mice were infected with various concentrations of the ACV-
resistant HSV-1 isolates by microinjection of 2.5 µl of the virus pre-
paration into the anterior eye chamber of the right eye. Intraocular
injections were performed with a 30-gauge needle attached to a 100 µl
microsyringe (Hamilton, Reno, NV). The incidence of ocular disease
was determined by light microscopy. Further experiments were per-
formed with the clinical isolate HSV-1 ACVr 1. Mice were infected with
5 × 103 PFU HSV-1 ACVr 1 as described above and systemically treated
with the parental murine (mAb 2c) or the humanized (mAb hu2c)
monoclonal antibody. The antibodies were applied intravenously by
injection of 300 µg mAb 2c or mAb hu2c either 24 h prior to infection
for pre-exposure prophylaxis (P), or 24, 40, and 56 h after infection for
post-exposure immunotherapy (PEP). Control mice were either mock
(PBS) treated or received ACV standard therapy at 10 mg/kg body
weight or high-dose therapy at 50 mg/kg body weight three times a day
(every 8 h) by intraperitoneal injection, starting at 24 h post infection.
Mice were sacriﬁced 12 days post infection. The incidence of ocular
disease was determined by light microscopy and hematoxylin-eosin
staining of the eye sections. Additionally, viral loads in the contralateral
eyes were measured on day 8 post infection with a standard plaque
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assay (N = 6 in each group).
2.6. Viral loads in the eye
Contralateral eyes of representative mice (n = 6 each group) were
enucleated on day 8 p.i. and immediately snap frozen. Subsequently,
the eyes were homogenized and serial 1:10 dilutions of the homogenate
were incubated on Vero cell monolayers for 1 h at 37 °C. The inocula-
tion medium was then removed and the monolayers were covered with
RPMI-agarose medium and incubated for 3 days. To determine the viral
load, the cells were ﬁxed and stained with 2% crystal violet. Plaques
were counted, and the number of PFU/ml was calculated based on the
dilution factor as previously described (Bauer et al., 2000).
2.7. Virus reactivation from trigeminal ganglia
The ipsi- and contralateral trigeminal ganglia (TGs) were explanted
on day 12 after infection and examined for HSV reactivation by co-
cultivation with Vero cells as previously described (Krawczyk et al.,
2015).
2.8. Histology
The incidence of retinal damage was investigated by light micro-
scopic examination of hematoxylin-eosin stained eye sections. For this
purpose, eyes were harvested on day 12 post infection, ﬁxed (64%
isopropanol, 3.7% formaldehyde, 2.5% acetic acid), dehydrated with
isopropanol, and embedded in paraﬃn. Five-micrometer sections were
then stained and analyzed as previously described (Hennig et al., 2012).
2.9. Statistical analysis
Data were analyzed using GraphPadPrism 5 (GraphPadPrism
Software, La Jolla, CA, USA).
The diﬀerences between the number of mice showing signs of ARN
and healthy mice (Fig. 2) or of latently infected trigeminal ganglions
and the number of trigeminal ganglions exhibiting reactivation (Fig. 4)
were examined by Fisher's exact test. Statistical analysis of the viral
loads in the eyes (Fig. 3) was performed with nonparametric ANOVA
(Kruskal–Wallis) and post hoc Dunn's multiple-comparisons test. Com-
parisons were considered signiﬁcant at *P< 0.05; **P< 0.01; and
***P<0.001.
3. Results
3.1. Pheno- and genotypic characterization of ACV resistant HSV-1 clinical
isolates
Three HSV-1 strains isolated from patients with severe HSK resistant
to antiviral treatment with ACV were used for the study. The isolates
were characterized as ACV-resistant with a phenotypic cell culture
assay (Fig. 1). The threshold for ACV-resistance was described with
2 µg/ml (equal to 8.89 µM) in prior studies (Bacon et al., 2003; Safrin
et al., 1994; Sauerbrei and Bohn, 2014). We therefore considered all of
the three isolates as ACV resistant. ACV resistance could be further
conﬁrmed by a genotypic characterization. The HSV-1 strain ACVr 2
exhibited a deletion of isoleucine at position 194 (I194del), and ACVr 3
the mutation M128L within the thymidine kinase (TK) gene. Both
mutations had been described as resistance-associated mutations
by Duan et al. (2009). The sequence analysis of the isolate ACVr 1 re-
vealed a substitution of threonine to arginine at amino acid position 66
(T66R) in a conserved region of the TK-gene. This mutation has not yet
been described, but former studies reported that mutations within the
conserved region of the TK are mainly associated with drug resistance
(Sauerbrei et al., 2016). The sequences of the conformational epitope
recognized by mAbs 2c and hu2c were conserved among the isolates
(Fig. 1). All three isolates were neutralized with the same eﬃcacy by
mAb 2c and hu2c (7.8 nM) as non-resistant HSV (data not shown).
3.2. Induction of ARN with ACV-resistant HSV-1 clinical isolates in BALB/c
mice
Strains of HSV-1 have been reported to vary in their pathogenesis
and neuroinvasiveness in mice (Wang et al., 2013). Therefore, we in-
itially tested the three ACV-resistant HSV-1 clinical isolates at diﬀerent
viral loads ranging from 1 × 103 PFU/2.5 µl to 1 × 105 PFU/2.5 µl for
their capacity to induce ARN in BALB/c mice. The HSV-1 ACV-resistant
strain 1 (van Velzen et al., 2013b) proved to be appropriate to induce
ARN in mice when used at 5 × 103 PFU/inoculation. Besides this, the
virus induced a pronounced inﬂammation of the anterior segment of
the contralateral eye. The histology of the contralateral eye showed a
strong retinal necrosis, comparable to the histological picture following
infection with the widely used HSV-1 KOS strain. The HSV-1 ACVr
isolate 3 revealed to be highly virulent and rapidly killed the mice
between day 5 and 8 before ARN was established, while HSV-1 ACVr
isolate 2 was low virulent and did not induce ARN (Fig. 1). We there-
fore selected the HSV-1 ACVr 1 isolate to conduct the following ex-
periments.
3.3. Prevention of HSV-1 ACVr-induced infection of the retina by mAbs 2c
and hu2c
To investigate the eﬃciency of mAb 2c and mAb hu2c in the pre-
vention of ARN, mice were infected with 5 × 103 PFU of the HSV-1
ACVr 1 isolate. The antibodies were systemically applied 24 h before
(pre-exposure prophylaxis (P)) or 24 h, 40 h and 56 h after infection
(post-exposure immunotherapy (PEP)). On day 12 post infection, the
contralateral eyes were examined for HSV-1 speciﬁc pathology in the
anterior part of the eye. In untreated control mice, 90% (9/10) of the
animals developed acute inﬂammation of the anterior eye segment with
corneal edema, iris vessel dilatation, mydriasis and posterior synechiae,
and ﬁbrin deposits on the lens (Fig. 2). Pathological changes of the
Fig. 1. Resistance proﬁle of three clinical HSV-1 isolates collected
from patients with HSK. (A) Three clinical isolates (HSV-1 ACVr
1, HSV-1 ACVr 2 and HSV-1 ACVr 3) resistant towards ACV were
titrated for their sensitivity to the antiviral drugs ACV, foscarnet
(FOS) and cidofovir (CDV) and tested for their pathogenicity in
the ARN mouse model. Resistance mutations within the viral
thymidine kinase gene were determined by sequencing and da-
tabase analysis with HSV reference sequences. The median in-
hibitory concentration (IC50) was deﬁned as the drug concentra-
tion that reduced viral loads by 50% when compared to untreated
control infected cells. The cutoﬀ value for aciclovir resistance was
IC50> 4 µmol/L, for foscarnet resistance IC50>300 µmol/L and
for cidofovir IC50> 10 µmol/L. (B) Conservation of the mAb hu2c
gB epitope sequences was examined by sequencing of the gB-gene
and is indicated at amino acid level. Motifs A
(179YSQFMGIFED188) and B (300FYGYRE305) forming the discontinuous epitope recognized by mAb hu2c are indicated in gray.
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retina were proven by histological analysis and conﬁrmed the clinical
characteristics of a severe retinal necrosis. A similar clinical picture and
a similar pronounced retinal necrosis was found in ACV-treated mice. In
contrast, antibody treated mice were eﬀectively protected from the
development of ARN. Mice treated with the murine antibody 2c showed
no signs of disease when applied before or after infection. A similar
therapeutic eﬀect was achieved with the humanized mAb hu2c. All but
one of the prophylactically mAb hu2c treated mice were protected from
severe ocular disease.
3.4. Eﬀect of antibody treatment on the viral load in the contralateral eye
To investigate the eﬀect of systemic antibody treatment with mAbs
2c or hu2c on the virus content in the eyes, six representative mice per
group mice were sacriﬁced on day 8 post infection. The contralateral
eyes were removed, shock-frozen and stored at −80 °C. To determine
the viral load, the specimens were homogenized at 4 °C and analyzed by
a standard plaque assay on Vero cells. As shown in Fig. 3, the con-
tralateral eyes of the control mice contained high viral loads. ACV-
treated mice showed slightly decreased viral loads in the eyes, but the
diﬀerence to controls was not statistically signiﬁcant. In contrast, there
was no virus detectable in the contralateral eyes of mice treated with
mAb 2c or mAb hu2c, irrespectively of whether the mice were treated
prophylactically (P) or a post-exposure prophylaxis (PEP) was given
(***P<0.001) (Fig. 3).
3.5. Reactivation of ACV-resistant HSV-1 from trigeminal ganglia
Almost all antibody-treated mice were completely protected from
the development of ARN, and there was no virus detectable in the
contralateral eyes. Therefore, we hypothesized that P or PEP treatment
with mAbs 2c or hu2c would be capable of inhibiting the cell-associated
transmission of HSV-1 from the periphery to the trigeminal ganglia. To
answer this question we isolated the TGs from the ipsilateral and the
contralateral site on day 12 post infection. The TGs were then co-cul-
tured with Vero cells for 3 weeks and daily checked for the develop-
ment of cytopathic eﬀects complying with virus reactivation. HSV-1
reactivation was found in the ipsilateral (10/10) and contralateral TGs
(9/10) of the untreated control mice. After standard-dose ACV treat-
ment (10 mg/kg), HSV reactivation was detected in 10/10 ipsilateral
and 8/10 contralateral TGs (Fig. 4). A slightly improved eﬀect could be
observed in mice treated with high-dose ACV (50 mg/kg). HSV re-
activation was observed in almost all ipsilateral TG (9/10) and 50% (5/
10) of contralateral TGs. The most pronounced eﬀects could be
achieved when monoclonal antibodies were used. There was a lower
number of HSV reactivating ipsilateral TGs of mAb 2c (P: 7/10; PEP: 8/
10) and hu2c (P: 9/10, PEP: 9/10) treated mice. In contrast, no re-
activation was observed in the contralateral TGs obtained from mAb 2c
treated mice (P: 0/10; PEP: 0/10). Similarly, in mAb hu2c treated mice,
reactivation was found only in one TGs (P: 0/10, PEP: 1/10). These
results indicate that the cell-associated transmission of ACV-resistant
HSV-1 from the site of primary infection (ipsilateral eye) to the con-
tralateral TGs was successfully inhibited by mAbs 2c and hu2c.
4. Discussion
Frequent reactivations of herpes simplex virus (HSV) from the tri-
geminal ganglia may lead to the recurrent infection of the cornea or
retina. Both manifestations may be associated with severe impairment
of sight or blindness. The treatment of ocular HSV infections can be
challenging, particularly due to the increasing emergence of ACV re-
sistances in patients suﬀering from ARN or HSK (Dokey et al., 2014;
Patel et al., 2010; Toriyama et al., 2014; Tran et al., 2005; van Velzen
Fig. 2. Eﬃcacy of mAbs 2c and hu2c in the prevention of ACV-resistant HSV-1 infection of the retina. (A) The contralateral eyes were examined at day 12 post infection for retinal disease
by light microscopy and histological staining and classiﬁed as pathologic or healthy. Healthy eyes were characterized by a normal clinical appearance and intact retina, whereas
pathologic eyes were impaired and showed extensive damage of the retinal tissue. (B) Percentages of mice (n = 10) with pronounced retinal necrosis. The impacts of antibody treatment
at 24 h before infection (P) or 24, 40 and 56 h after infection (PEP) were compared with mock (PBS) or high-dose ACV (50 mg/mg) treated mice and statistical signiﬁcances were
determined with the Fisher´s exact test. Comparisons were considered signiﬁcant at *P< 0.05; **P<0.01; and ***P<0.001.
Fig. 3. Potent protection of the contralateral eyes against HSV-1 infection by systemically
applied mAbs 2c or hu2c. Eyes were removed on day 8 post infection, homogenized and
tested for viral loads using a standard plaque assay. The impacts of antibody treatment at
24 h before infection (P) or 24, 40 and 56 h after infection (PEP) were compared with
mock (PBS) treated mice and statistical signiﬁcances were determined with a nonpara-
metric ANOVA (Kruskal–Wallis) and post hoc Dunn's multiple-comparisons test.
Comparisons were considered signiﬁcant at *P< 0.05; **P< 0.01; and ***P< 0.001.
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et al., 2013b)
Due to the persistent need to improve the conventional therapy and
to overcome drug resistant ocular infections, we investigated the anti-
viral eﬃciency of mAb hu2c toward an ACV-resistant clinical isolate in
the mouse model of acute retinal necrosis. Monoclonal antibodies were
described as a potent tool for the treatment of HSV infections (Atherton,
1992; Eis-Hubinger et al., 1993; Krawczyk et al., 2013, 2015; Metcalf
et al., 1988, 1987).
We hypothesized that the HSV-1/2-gB speciﬁc, humanized mono-
clonal antibody mAb hu2c, developed by our group might be a good
candidate for the prevention of ACV-resistant ocular infections. The
epitope recognized by this antibody is highly conserved among a broad
range of HSV1/2-isolates and essential for viral ﬁtness (Daumer et al.,
2011). The unique feature of this antibody is its ability to completely
abort the cell-to-cell transmission of the virus, which makes it superior
to polyclonal HSV-neutralizing human antibodies (Krawczyk et al.,
2013, 2011). Cell-to-cell spread is used by HSV to escape from the host's
immune response. This mechanism is usually unassailable by human
antibodies and requires among others the viral glycoprotein gB (Cocchi
et al., 2000; Sattentau, 2008a, 2008b). The superiority of the parental
murine antibody to neutralizing human antibodies was demonstrated in
a prior study in the murine genital herpes model (Eis-Hubinger et al.,
1993). The assessment of ARN requires an eﬀective anterograde-di-
rected transport of HSV from the trigeminal ganglia to the retina that
proceeds over the cell-associated cell-to-cell transmission of the virus
(Al-Dujaili et al., 2011). The HSV-1 ACVr 1 isolate from a patient suf-
fering from HSK used for the mouse study was characterized by
phenotypic analysis as resistant toward aciclovir. The mutation found
in the TK-gene (T66R) might be responsible for the ACV resistance
(Sauerbrei et al., 2016). Additionally, we found a mutation in the
polymerase gene (D672N), which also might be associated with re-
sistance (Burrel et al., 2010; Sauerbrei et al., 2010). Further in-
vestigations are needed to clarify the exact impact of these mutations
on ACV resistance. The recommended regime for the treatment of ARN
in humans is intravenous application of acyclovir at 10 mg/kg every 8
hours per day (Tam et al., 2010). In infants with CNS disease suﬀering
from herpes neonatorum doses of 40–60 mg/kg are used (Kimberlin
et al., 2001). Accordingly, we applied aciclovir at the standard dosage
(10 mg/kg) or as high-dose therapy (50 mg/kg) in our study. ACV
completely failed to protect the mice from ARN at 10 mg/ml and was
only 50% eﬀective at 50 mg/ml. The data indicate that high-dose ACV
therapy may improve the clinical outcome of infection resistant to
standard treatment regimens (Kim et al., 2011). In contrast to ACV
treatment, systemically applied mAbs 2c or hu2c eﬀectively protected
mice from ARN when applied at 24 h before or 24 h, 40 h and 56 h after
infection. In this model, the viral transmission from the infected eye to
the ipsilateral eye could not be inhibited by mAb 2c or mAb hu2c. The
best protective eﬀect was achieved when mAb 2c was applied at 24 h
before infection, since there was no virus detectable in 3/10 ipsilateral
ganglia. According to prior studies describing the ARN mouse model,
the mice were observed for 12 days (Atherton, 1992). The average
biological half-life is assumed with 22.4 days for total IgG antibodies
(Thurmann et al., 1995). Hence, it is possible that there might be some
persistent virus present after day 12 that might cause disease at later
time points when the level of antibody already begins to wane.
With one exception (mAb hu2c PEP group), no virus could be re-
activated from the contralateral ganglia of antibody treated mice.
Consistent with our previous ﬁndings, our data indicate that the
monoclonal antibodies not only neutralize the secreted virus but also
abort the cell-associated viral transmission between cells and neurons
(Krawczyk et al., 2015). Although HSV could be neither detected by cell
culture reactivation assay nor by PCR ampliﬁcation of HSV-DNA from
the contralateral trigeminal ganglia (data not shown), further ex-
aminations are needed to clarify the underlying mechanism by which
the antibody blocks the anterograde transmission of HSV. However,
limiting the neuronal spread of the virus is crucial for the eﬀective
protection from ARN. Our ﬁndings are consistent with a prior study
demonstrating that a monoclonal antibody (8D2) targeting a type-
common epitope of glycoprotein D was eﬀective in protecting from
ARN (Atherton, 1992). Although the mode of action was not completely
resolved, the authors hypothesized that this antibody may protect by
blocking the viral spread through the central nervous system.
The murine ARN model used in this study mimics the anterograde-
directed neuronal spread of HSV and the development of ocular infec-
tion in humans, but has some limitations. Most important, in contrast to
some species like humans or rabbits, mice do not exhibit spontaneous
reactivations of HSV (Gebhardt and Halford, 2005). Second, the course
of infection diﬀers between humans and mice. Humans are treated after
the onset of symptoms. In contrast, HSV-relating symptoms are almost
completely irreversible in mice. Therefore, potential antivirals are
commonly applied up to 24 h post infection as post-exposure prophy-
laxis, after the establishment of infection but before the onset of
symptoms (Kleymann et al., 2002; Palliser et al., 2006). Animal studies
with ACV go back to the 1970's, when ACV was examined in experi-
mental herpes simplex encephalitis in mice. The treatment was initiated
12 h post infection with a lethal HSV dose (Park et al., 1979). In hu-
mans, ACV was highly eﬀective and became the golden standard for the
treatment of HSV infections. The drug is commonly applied after the
onset of infection or as prophylaxis in high-risk patients such as bone
marrow transplants. In our study, the eﬃcacy of mAb hu2c was com-
pared to ACV, and we found that this antibody was highly eﬀective in
protecting mice from the development of ARN. We believe that this
antibody may become a novel therapeutic option for ARN in humans,
Fig. 4. Reactivation of ACV-resistant HSV-1 from trigeminal ganglia of mice systemically
treated with mAbs 2c or hu2c. The percentages of reactivating ipsilateral or contralateral
trigeminal ganglia from HSV-1 ACVr 1 infected mice (n = 10) are shown. Trigeminal
ganglia were harvested on day 12 after infection and co-cultured with Vero cells for three
weeks. The occurrence of a cytopathic eﬀect typical for HSV was considered as re-
activation. The diﬀerences in the total numbers of reactivating ganglia between the an-
tibody treatment groups and the PBS or ACV (50 mg/kg) group were compared and
statistical signiﬁcances were determined with the Fisher´s exact test. Comparisons were
considered signiﬁcant at *P< 0.05; **P< 0.01; and ***P< 0.001.
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and a good alternative to ACV. In humans, mAb hu2c may be used as
prophylactic treatment in patients suﬀering from frequent reactivations
of ocular herpes simplex virus, thereby preventing the damage of the
eye and protecting from disease. Furthermore, mAb hu2c may be used
for the treatment of ﬂorid ocular HSV infections to stop the progression
of disease.
In conclusion, our results demonstrate the antiviral potency of the
humanized mAb hu2c in the prevention of drug resistant HSV-infec-
tions of the eye. The antibody might be further evaluated for its clinical
use in Phase I and II trials. We are highly conﬁdent that mAb hu2c will
become a potent treatment option for patients with severe ocular dis-
eases caused by ACV- and multi-resistant herpes simplex viruses, which
are a major cause of blindness world wide.
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